Illumina Inc (ILMN) Files Form 4 Insider Selling : Robert S Epstein Sells 300 Shares

Illumina Inc (ILMN): Robert S Epstein , director of Illumina Inc sold 300 shares on Sep 20, 2016. The Insider selling transaction was reported by the company on Sep 21, 2016 to the Securities and Exchange Commission. The shares were sold at $174.29 per share for a total value of $52,287.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 16, 2016, Marc Stapley (EVP & Chief Administrative Ofc) sold 1,270 shares at $172.38 per share price.On Sep 16, 2016, Daniel Bradbury (director) sold 600 shares at $171.04 per share price.Also, On Sep 8, 2016, Charles Dadswell (Sr VP & General Counsel) sold 116 shares at $168.01 per share price.On Aug 24, 2016, Robert S Epstein (director) sold 300 shares at $170.27 per share price.

Illumina: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in Illumina which led to swings in the share price. The shares opened for trading at $174.29 and hit $177.47 on the upside , eventually ending the session at $175.8, with a gain of 1.53% or 2.65 points. The heightened volatility saw the trading volume jump to 7,86,856 shares. The 52-week high of the share price is $209.9899 and the company has a market cap of $25,772 M . The 52-week low of the share price is at $127.1.

Illumina Money Flow Index Chart

Company has been under the radar of several Street Analysts.Illumina is Downgraded by CL King to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Aug 22, 2016.Illumina is Reiterated by Mizuho to Neutral and the brokerage firm has raised the Price Target to $ 148 from a previous price target of $138 .The Rating was issued on Jul 27, 2016.Illumina is Downgraded by Morgan Stanley to Underweight while Lowering the Price Target of the company shares to $ 110 from a previous price target of $130 . Earlier the firm had a rating of Equal-Weight on the company shares. The Rating was issued on Jul 5, 2016.

Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.

Leave a Reply

Illumina - Is it time to Sell?

Top Brokerage Firms are advising their investors on Illumina. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.